drugset / Trial / NCT07085091
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Timeline
- Start
- 2025-08-18
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALX2004 | Unknown | — | Intravenous |